Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial - Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Keedy, Vicki (Vanderbilt University Medical Center) ; Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ; Shepherd, Frances A. (University of Toronto) ; Insa, Amelia (Hospital Clínic Universitari (València)) ; Brown, Holly (Merck & Co., Inc., Whitehouse Station) ; Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ; Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ; Reilly, John F.. (Merck & Co., Inc., Whitehouse Station) ; Mauro, David (Merck & Co., Inc., Whitehouse Station) ; Hsu, Karl (Sanofi Aventis) ; Yan, Li (Merck & Co., Inc., Whitehouse Station) ; Universitat Autònoma de Barcelona
 
Comments (0) | Reviews (0)
Start a discussion about any aspect of this document.

 Subscribe to this discussion. You will then receive all new comments by email.

Add comment


Once logged in, authorized users can also attach files.
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.
          You can use some HTML tags: <a href>, <strong>, <blockquote>, <br />, <p>, <em>, <ul>, <li>, <b>, <i>